As of the time of writing, the stock has risen by 10%, priced at $4.4.
According to the Zhitong Financial APP, on Tuesday, the biotechnology company Jupiter Neurosciences (JUNS.US) debuted on the US stock market. As of the time of writing, the stock has risen by 10%, priced at $4.4. Jupiter Neurosciences is developing a unique platform product based on resveratrol, primarily for the treatment of neuroinflammation. The company believes that its main candidate drug JOTROL holds promise for treating various neurological and rare diseases. JOTROL completed Phase I safety and tolerability trials in March 2021, and Jupiter plans to initiate Phase II trials after the IPO is completed.
